Answers are grounded in this paper and cite their sources.
This viewpoint identifies regulatory loopholes in tetrahydrocannabinol sale, suggesting increased oversight and funding to address gaps.
This Viewpoint identifies regulatory loopholes in the legal manufacture and sale of nonmedical products with intoxicating tetrahydrocannabinol levels in the US, and it calls for increased congressional oversight and research funding to address these regulatory gaps.
No takes yet. Share an insight, caveat, or question.
Nippler et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: